Sat.Sep 26, 2020 - Fri.Oct 02, 2020

article thumbnail

Life science leaders sign new ‘Biotech Social Pact’ for Europe

pharmaphorum

The signatories of a new Biotech Social Pact with Europe and patients explain why healthcare calls for a new social contract, not a pharmaceutical strategy. As Europe continues its efforts to battle the Covid-19 pandemic, it is rightfully focusing its attention on the longer-term implications of this crisis. One common thread is clearly emerging from EU and national discussions: to reinforce Europe’s “strategic autonomy” and “technological sovereignty” in key industrial sectors.

141
141
article thumbnail

Novel nasal spray reduces viral replication by up to 96%: according to COVID-19 challenge study

Outsourcing Pharma

Ena Respiratoryâs preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.

133
133
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New patent for NOVO drug OZEMPIC

Drug Patent Watch

Annual Drug Patent Expirations for OZEMPIC Ozempic is a drug marketed by Novo and is included in one NDA. It is available from three suppliers. There are twenty-two patents protecting…. The post New patent for NOVO drug OZEMPIC appeared first on DrugPatentWatch - Make Better Decisions.

98
article thumbnail

Accenture reveals data science project for paediatric leukaemia

Pharma Times

Insights from project could potentially improve precision medicine use for paediatric AML

131
131
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

FDA launches Digital Health Center of Excellence

pharmaphorum

The FDA has launched its Digital Health Center of Excellence (DHCoE), as the agency continues with its commitment to advancing use of technology such as mobile health devices, software and wearables to create medical products. Housed within the agency’s Center for Devices and Radiological Health, the DHCoE is part of a wider strategy to encourage development of digital health products and therapeutics.

138
138
article thumbnail

FSD Pharma Phase II COVID-19 trial gets go-ahead

Outsourcing Pharma

The companyâs Phase II trial of ultramicronized PEA has received FDA approval and expects to begin dosing patientparticipants as early as next month.

122
122

More Trending

article thumbnail

First UK patient given GSK’s experimental arthritis drug in COVID-19 trial

Pharma Times

Drug is being investigated in up to 800 hospitalised patients nationwide

140
140
article thumbnail

Regeneron’s antibody cocktail active against coronavirus, cuts symptoms

pharmaphorum

Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. This first data comes from a descriptive analysis from the seamless phase 1/2/3 trial that Regeneron hopes will hurry the medicine dubbed REGN-COV2 to market. The ongoing double-blind trial measures the effect of adding REGN-COV2 to usual standard of care, compared with usual standard of care.

Immunity 135
article thumbnail

Berg fuels study of African-American COVID-19 patients

Outsourcing Pharma

Results from the research indicate use of ACE in inhibitors and ARBs could prove useful in treating COVID-19 patients of African-American descent.

96
article thumbnail

Could the Amazon Save Your Life?

NY Times

Scientists are looking at the medicinal potential of plants and animals in the region’s vast tropical forests.

78
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Novacyt signs deal with UK government for COVID-19 testing kits

Pharma Times

First phase will see company deploy 300 PCR instruments to the UK

144
144
article thumbnail

The new pharma collaborations driving transformative research in oncology

pharmaphorum

The pharmaceutical industry is one of the most scientifically innovative and competitive industries, particularly in oncology. As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies. As a result, there is a need for continued innovation and increased efficiency in terms of drug development to manage cost, complexity and speed to provide potentially transformative therapies for cancer patients.

article thumbnail

Italy and India the only pharma economies to improve score in 2020 according to the CPhI Pharma Index

Pharma Mirror

Ahead of the CPhI Festival of Pharma (5-16 October, 2020) – global pharma’s largest ever virtual gathering – the CPhI Pharma Index shows only Italy and India have improved their score in 2020, with the majority of industry executives looking for new supply chain partners. The Index – an aggregated confidence score across the five. The post Italy and India the only pharma economies to improve score in 2020 according to the CPhI Pharma Index appeared first on Pharma Mirror Magazine.

59
article thumbnail

RedHill’s Phase II/III COVID-19 research gets green light

Outsourcing Pharma

The companyâs studies exploring the use of opaganib in severe COVID-19 patients have been approved in Brazil and other countries around the globe.

95
article thumbnail

Gilead’s oral JAK inhibitor filgotinib wins EU approval

Pharma Times

Treatment is indicated for use in adults with moderate-to-severe active rheumatoid arthritis

125
125
article thumbnail

Agents for change: the women breaking through in life sciences venture capital

pharmaphorum

For a long time, venture capital (VC) firms have been controlled mainly by men. But things are changing and women are becoming more influential in life sciences VCs, with an increase in business going to all-female teams. We spoke with two female VC leaders about how women could act as agents for change in this male-dominated world. Last year saw a record amount of venture capital – $17.2 billion – raised by women, according to the financial information company Pitchbook.

118
118
article thumbnail

New patent expiration for Boehringer Ingelheim drug OFEV

Drug Patent Watch

Annual Drug Patent Expirations for OFEV Ofev is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent expiration for Boehringer Ingelheim drug OFEV appeared first on DrugPatentWatch - Make Better Decisions.

52
article thumbnail

RedHill’s Phase II/III COVID-19 research underway

Outsourcing Pharma

The companyâs studies exploring the use of opaganib in severe COVID-19 patients have been approved in Brazil and other countries around the globe.

64
article thumbnail

Cancer Research UK calls on government to address cancer inequality

Pharma Times

New report finds 60 cancer cases per day could be avoided in less wealthy areas

128
128
article thumbnail

Valirx eyes partnerships as first VAL201 study hits the mark

pharmaphorum

Shares in UK biotech Valirx were up sharpy this morning after its lead drug VAL201 showed evidence of efficacy in advanced prostate cancer in its first clinical trial. The company reported results from 11 patents taking part in the phase 1/2 study which showed a 54.5% overall response rate with VAL201, with a promising safety and tolerability profile.

Hospitals 116
article thumbnail

Bridging Data Insights Across the Patient Journey to Inform Your Commercialization Strategy

Drug Channels

Today’s guest post comes from Jenna Mitby-Manning, Senior Director of Commercial Strategy & Insights, Access & Adherence at RxCrossroads by McKesson. Jenna explains how data-driven solutions accelerate time to therapy, improve patient outcomes, and allow biopharma companies to make informed strategic decisions. Click here to learn more about RxCrossroads' therapy access and adherence solutions.

52
article thumbnail

Syntegon goes live at PACK EXPO Connects 2020

Pharma Mirror

Since the in-person PACK EXPO International and Healthcare Packaging EXPO have been cancelled, the process and packaging technology specialist Syntegon is presenting its latest solutions at the virtually-hosted PACK EXPO Connects from November 9 to 13, 2020. In a series of video and Q&A sessions, Syntegon is showcasing its intelligent and sustainable technologies for the.

article thumbnail

MHRA deems Sanofi’s avalglucosidase alfa ‘promising’ for Pompe disease

Pharma Times

New therapy granted a Promising Innovative Medicine designation by UK agency

124
124
article thumbnail

Careology teams up with private GP group on COVID-19 monitor

pharmaphorum

A digital tool that allows doctors to monitor patients with COVID-19 remotely in real time and intervene when treatment is needed has been launched in the UK. The mobile app – developed by digital heath specialist Careology – provides advice on COVID-19 symptoms and links patients with doctors at the London General Practice, a private GP group with around 50,000 people on its books, via online video consultations.

114
114
article thumbnail

New patent for Chiesi drug CARDENE

Drug Patent Watch

Annual Drug Patent Expirations for CARDENE Cardene is a drug marketed by Chiesi and is included in three NDAs. It is available from two suppliers. There are four patents protecting…. The post New patent for Chiesi drug CARDENE appeared first on DrugPatentWatch - Make Better Decisions.

52
article thumbnail

6 Reasons Why Ranitidine Is Harmful and How It Caused Cancer to Many

Pharma Mirror

Ranitidine is a pharmaceutical drug that is categorized as a histamine antagonist, also called an H2 blocker, that has popularly been used to treat acid reflux. However, this medication had recently raised controversies when the Food and Drug Administration (FDA) announced a product recall of this drug from the market due to the presence of. The post 6 Reasons Why Ranitidine Is Harmful and How It Caused Cancer to Many appeared first on Pharma Mirror Magazine.

52
article thumbnail

NeuroRx and Relief Therapeutics sign new supply agreements for COVID-19 drug

Pharma Times

Supply chain agreements come before upcoming data readout

137
137
article thumbnail

UK pledges £571m to equitable COVID-19 vaccine access scheme

pharmaphorum

UK Prime Minister Boris Johnson has told the UN General Assembly that the UK will donate £571 million ($735 million) to the COVAX scheme aimed at distributing COVID-19 vaccines fairly around the world. The lion’s share of that total – around £500 million – will be “for developing countries to protect themselves,” said the PM in a recorded speech given to the assembly, delivered just before the number of deaths due to coronavirus topped 1 million worldwide.

Vaccines 113
article thumbnail

New patent for Chiesi drug CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

Drug Patent Watch

Annual Drug Patent Expirations for CARDENE+IN+0.83%25+SODIUM+CHLORIDE+IN+PLASTIC+CONTAINER Cardene In 0.83% Sodium Chloride In Plastic Container is a drug marketed by Chiesi and is included in one NDA. It is available from…. The post New patent for Chiesi drug CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER appeared first on DrugPatentWatch - Make Better Decisions.

52
article thumbnail

Biocartis Receives EUR 1.2 million Grant for Development of Highly Innovative Idylla™ GeneFusion Assay

Pharma Mirror

Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has received a EUR 1.2 million grant from VLAIO, the Flanders organization for Innovation & Entrepreneurship, for the development of the highly innovative GeneFusion Assay on its easy, rapid molecular and fully automated diagnostics platform Idylla™.

52
article thumbnail

Sosei Heptares scores $5m milestone payment from Pfizer

Pharma Times

First subject dosed with new drug candidate from strategic collaboration

125
125
article thumbnail

Field Trip becomes latest psychedelic firm to go public

pharmaphorum

Psychedelic therapy company Field Trip Psychedelics has announced that it will soon join the growing list of psychedelic companies going public. . Through a direct listing on the CSE, the company expects trading to begin on 7 October after entering into an amalgamation agreement in August with Newton Energy Corp. Field Trip aims to “take a personalised approach to mental wellness” by blending legal psychedelic-enhanced therapy, mindfulness, and self-care with a series of sessions with trained ps

article thumbnail

New patent for Chiesi drug CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

Drug Patent Watch

Annual Drug Patent Expirations for CARDENE+IN+0.86%25+SODIUM+CHLORIDE+IN+PLASTIC+CONTAINER Cardene In 0.86% Sodium Chloride In Plastic Container is a drug marketed by Chiesi and is included in one NDA. It is available from…. The post New patent for Chiesi drug CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER appeared first on DrugPatentWatch - Make Better Decisions.

52
article thumbnail

Drug Channels News Roundup, September 2020: FQHCs and 340B, Drug Prices, CVS Health’s Zinc, Telehealth, All-Time Greatest Songs, and 10K on Twitter

Drug Channels

Autumn is here! We’ve been squirrelling away these acorns from the mighty Drug Channels oaks: I agree. FQHCs are not the problem in 340B. Brand-name drugs prices keep on dropping It’s official: CVS Health’s Zinc GPO actually exists! Telehealth takes a dive Plus, vote for your 10 favorite songs of all time! P.S. This month, @DrugChannels exceeded 10,000 followers on Twitter.

article thumbnail

Data shows coronavirus infection rate might be slowing

Pharma Times

The R rate has fallen but prevalence of infection is at a record level

123
123